Pierre Ferré

886 total citations
30 papers, 433 citations indexed

About

Pierre Ferré is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pierre Ferré has authored 30 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pierre Ferré's work include Cancer Treatment and Pharmacology (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Pierre Ferré is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and CAR-T cell therapy research (5 papers). Pierre Ferré collaborates with scholars based in France, United States and Germany. Pierre Ferré's co-authors include Ted Whittem, Qiang Li, Hervé P. Lefebvre, Kirby Pasloske, Emmanuelle Uro‐Coste, Fabien Corbière, Jacques Grassi, F. Schelcher, A. Chabert and Gilles Foucras and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Pierre Ferré

29 papers receiving 422 citations

Peers

Pierre Ferré
Ruth Tal Israel
Kuan‐I Lee Taiwan
Marina Gomes Miranda e Castor Brazil
Amber Wolfe United States
Sarah A. Bingel United States
N. Hauser Belgium
Masakazu Shimada Japan
Jonathan Vazquez‐Perez United States
Leila Reyes Australia
Toshiho Nishita Japan
Ruth Tal Israel
Pierre Ferré
Citations per year, relative to Pierre Ferré Pierre Ferré (= 1×) peers Ruth Tal

Countries citing papers authored by Pierre Ferré

Since Specialization
Citations

This map shows the geographic impact of Pierre Ferré's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Ferré with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Ferré more than expected).

Fields of papers citing papers by Pierre Ferré

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Ferré. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Ferré. The network helps show where Pierre Ferré may publish in the future.

Co-authorship network of co-authors of Pierre Ferré

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Ferré. A scholar is included among the top collaborators of Pierre Ferré based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Ferré. Pierre Ferré is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sharma, Manish, Anne M. Noonan, Daniel A. Vaena, et al.. (2024). Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.. Journal of Clinical Oncology. 42(16_suppl). 3597–3597. 1 indexed citations
2.
Alteber, Zoya, Gady Cojocaru, Dan Blat, et al.. (2023). 550 Harnessing natural IL-18 activity through IL-18BP blockade reshapes the tumor microenvironment for potent anti-tumor immune response. SHILAP Revista de lepidopterología. A624–A628.
3.
Pétain, Aurélie, Dafang Zhong, Xiaoyan Chen, et al.. (2019). Effect of ethnicity on vinorelbine pharmacokinetics: a population pharmacokinetics analysis. Cancer Chemotherapy and Pharmacology. 84(2). 373–382. 4 indexed citations
4.
5.
Tufman, Amanda, Joachim von Pawel, Achim Rittmeyer, et al.. (2017). Metronomic treatment of advanced non-small-cell lung cancer with daily oral vinorelbine – a Phase I trial. OncoTargets and Therapy. Volume 10. 1081–1089. 17 indexed citations
6.
Tierny, Dominique, François Serres, Emmanuel Bouchaert, et al.. (2015). Phase I Clinical Pharmacology Study of F14512, a New Polyamine-Vectorized Anticancer Drug, in Naturally Occurring Canine Lymphoma. Clinical Cancer Research. 21(23). 5314–5323. 19 indexed citations
7.
Thibault, Benoît, Emily Clement, Samuel Meignan, et al.. (2015). F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer. Cancer Letters. 370(1). 10–18. 20 indexed citations
8.
Delord, Jean‐Pierre, Alain Ravaud, Jaafar Bennouna, et al.. (2012). Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction. Investigational New Drugs. 31(3). 724–733. 5 indexed citations
9.
Delord, Jean‐Pierre, et al.. (2012). Vinflunine Oral Pharmacokinetics and Absolute Bioavailability of Soft and Hard Gelatin Capsules. Clinical Pharmacokinetics. 51(6). 357–364. 2 indexed citations
10.
Paridaens, Robert, et al.. (2012). A phase 1 study of vinflunine in combination with trastuzumab for the treatment for HER2-positive metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 70(4). 503–511. 4 indexed citations
11.
Calvo, Emiliano, Jan B. Vermorken, Sandrine Hiret, et al.. (2012). Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. Cancer Chemotherapy and Pharmacology. 69(6). 1467–1475. 3 indexed citations
12.
Delord, J.P., Nicolás Isambert, P. Fumoleau, et al.. (2011). Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer.. Journal of Clinical Oncology. 29(15_suppl). 2570–2570. 1 indexed citations
13.
Tournoux‐Facon, Caroline, et al.. (2011). Phase I and Pharmacokinetic Study of IV Vinflunine in Combination With Carboplatin in Chemonaive Patients With Advanced Non-small Cell Lung Cancer. American Journal of Clinical Oncology. 35(4). 378–385. 5 indexed citations
14.
Ferré, Pierre, Laurence Liaubet, Didier Concordet, et al.. (2007). Longitudinal Analysis of Gene Expression in Porcine Skeletal Muscle After Post-Injection Local Injury. Pharmaceutical Research. 24(8). 1480–1489. 28 indexed citations
15.
Chanoit, Guillaume, Pierre Ferré, & Hervé Lefèbvre. (2007). Chronic lymphatico-venous bypass: surgical technique and aftercare in a porcine model. Interactive Cardiovascular and Thoracic Surgery. 6(6). 705–707. 2 indexed citations
16.
17.
Ferré, Pierre, et al.. (2006). Plasma pharmacokinetics of alfaxalone in dogs after an intravenous bolus of Alfaxan-CD RTU. Veterinary Anaesthesia and Analgesia. 33(4). 229–236. 147 indexed citations
18.
Dupouy, Véronique, et al.. (2005). Time course of COX-1 and COX-2 expression during ischemia-reperfusion in rat skeletal muscle. Journal of Applied Physiology. 100(1). 233–239. 24 indexed citations
19.
Andréoletti, Olivier, Stéphanie Simon, Caroline Lacroux, et al.. (2004). PrPSc accumulation in myocytes from sheep incubating natural scrapie. Nature Medicine. 10(6). 591–593. 94 indexed citations
20.
Ferré, Pierre, Didier Concordet, Valérie Laroute, et al.. (2001). Comparison of ultrasonography and pharmacokinetic analysis of creatine kinase release for quantitative assessment of postinjection muscle damage in sheep. American Journal of Veterinary Research. 62(11). 1698–1705. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ruth Tal Breakdown of academic impact, for papers by Kuan‐I Lee Breakdown of academic impact, for papers by Marina Gomes Miranda e Castor Breakdown of academic impact, for papers by Amber Wolfe Breakdown of academic impact, for papers by Sarah A. Bingel Breakdown of academic impact, for papers by N. Hauser Breakdown of academic impact, for papers by Masakazu Shimada Breakdown of academic impact, for papers by Jonathan Vazquez‐Perez Breakdown of academic impact, for papers by Leila Reyes Breakdown of academic impact, for papers by Toshiho Nishita
Rankless by CCL
2026